This is an open-label, single-arm, multicenter, Phase I/Phase II clinical activity and safety study in patients with advanced, relapsed non-Hodgkin's B-ce lymphoma. Patients with low- or intermediate-grade NHLs who have relapsed disease or have failed primary conventional therapy and now require treatment will be eligible for this study.
Showing the most recent 10 out of 1085 publications